HC Wainwright Reaffirms Buy Rating for TransCode Therapeutics (NASDAQ:RNAZ)

HC Wainwright reiterated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ) in a research report sent to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $3.00 price objective on the stock.

TransCode Therapeutics Stock Down 9.6 %

Shares of TransCode Therapeutics stock opened at $0.59 on Thursday. TransCode Therapeutics has a twelve month low of $0.22 and a twelve month high of $19.42. The company has a fifty day moving average price of $0.44 and a 200 day moving average price of $0.70.

TransCode Therapeutics (NASDAQ:RNAZ) last issued its earnings results on Wednesday, August 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.16). Equities research analysts expect that TransCode Therapeutics will post -2.06 earnings per share for the current fiscal year.

Institutional Trading of TransCode Therapeutics

A hedge fund recently bought a new stake in TransCode Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned approximately 0.84% of TransCode Therapeutics at the end of the most recent quarter.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.